Who makes Nebivolol II?

Nebivolol II is developed by Trinity Hypertension & Metabolic Research Institute.

What development phase is Nebivolol II in?

Nebivolol II is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Nebivolol II

Trinity Hypertension & Metabolic Research Institute · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Nebivolol II
Also known as	Metoprolol II
Sponsor	Trinity Hypertension & Metabolic Research Institute
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients (PHASE4)
Efficacy and Safety of Nebivolol Versus Metoprolol in Hypertensive Subject Taking Amlodipine (PHASE4)
The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Nebivolol II CI brief — competitive landscape report
Nebivolol II updates RSS · CI watch RSS
Trinity Hypertension & Metabolic Research Institute portfolio CI